Impella微轴流左心室辅助装置作为儿童终末期心脏病心脏移植桥接的疗效
该研究基于UNOS登记数据(2018年1月至2024年7月),分析Impella在儿童心脏移植等待者中的使用趋势与结局。Impella队列59例,中位年龄14岁,71%在Impella支持期间接受移植,5例等待期死亡,移植后3年生存率与其它器械支持或无机械支持组无显著差异。
要点
- Impella在儿童心脏移植桥接中使用逐渐增加,早期结局良好。
- 59例Impella患儿中71%在支持期间接受移植,中位支持15天。
- 移植后3年生存率与其它器械或无机械支持组无统计学差异。
核心结论
- Impella在儿童作为心脏移植桥接的使用增加,早期结局良好。
- Impella 5.5可能因高流量能力和移动潜力促进了这一趋势。
- 移植后3年生存率在Impella、其它器械和无器械支持组间无统计学显著差异。
研究设计与样本
- 分析UNOS登记库2018年1月至2024年7月所有列入心脏移植的儿童数据。
- 采用Kaplan-Meier分析评估纵向结局,比较Impella、其它器械支持和无机械支持三组。
- Impella队列共59例儿童,列出时中位年龄14岁(IQR 13-16),移植时15岁(IQR 13-16)。
主要发现
- Impella使用随时间稳步增加。
- 基础病因:心肌病75%(n=44),先天性心脏病14%(n=8),其他12%(n=7)。
- Impella类型:5.0/5.5占59%(n=35),CP占33%(n=20),RP占8%(n=4)。
临床怎么用
- Impella可作为儿童终末期心脏病患者桥接心脏移植的过渡支持选择。
- 需进一步评估其优势、疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Impella microaxial left ventricular assist device (Abiomed) is increasingly used in adults as extended support bridging to heart transplantation. In recent years, its off-label use in children has also expanded. This review summarizes current experiences with Impella support in pediatric patients listed for heart transplantation and compares outcomes with contemporaneous cohorts who either received no support or other ventricular assist device support. METHODS: We analyzed data from the United Network for Organ Sharing registry between January 2018 and July 2024, including all children listed for heart transplantation. Longitudinal outcomes were assessed using Kaplan-Meier analysis, with comparisons made between children supported with Impella, those receiving other device support, and those managed without mechanical support. RESULTS: Impella utilization increased steadily over time. The Impella cohort included 59 children, with a median age of 14 years (interquartile-range 13-16) at listing and 15 years (interquartile-range 13-16) at transplant. The underlying pathologies were: cardiomyopathy (75%,n=44), congenital heart disease (14%,n=8), and other conditions (12%,n=7). Impella device types used were: 5.0/5.5 (59%,n=35), CP (33%,n=20), and RP (8%,n=4). Ten patients (17%) were converted to durable ventricular assist device with a median support of 5 days (interquartile-range 2-11). Forty-two patients (71%) received transplantation while on Impella support (median 15 days, interquartile-range 8-22). Five patients (8%) died while awaiting transplantation. Among those who received transplantation, four deaths occurred during follow-up. Three-year post-transplant survival was not statistically significantly different for children who received Impella, other device, and no device prior to transplantation. CONCLUSION: Impella use in children as a bridge to heart transplantation has increased, with favorable early outcomes. The Impella 5.5 has contributed to this trend, likely due to its high-flow capacity and mobility potential. Further assessment of its advantages, efficacy, and safety is needed.
引用
- Alsoufi B, Kozik D, Oelkers B, et al. Efficacy of Impella Microaxial left ventricular assist device as bridge to transplant in children with end stage heart disease. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 41092020. doi:10.1093/icvts/ivaf249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。